Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Non Small Cell Lung Carcinoma NSCLC 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Triple Negative Breast Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Genital Neoplasms, Female 1Genital Diseases, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Endocrine System Diseases 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cisplatin 2pembrolizumab 1durvalumab 1anlotinib 1Taxes 1Radiotherapy, Intensity-Modulated 1Pemetrexed 1Paclitaxel 1Nimorazole 1Immunotherapy 1Cell Count 1CP protocol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Glandular and Epithelial × CP protocol × Clear all
NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Active not recruiting
56 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡